© 2001 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects
INSERM Unité 367, 17 Rue du Fer à Moulin, 75005 Paris, France
bankir{at}ifm.inserm.fr
* Tel.: +33-1-45-8761-21; fax: +33-1-45-35-6629 or +33-1-47-46-9956
(1) Vasopressin (VP), or antidiuretic hormone, is secreted in response to either increases in plasma osmolality (very sensitive stimulus) or to decreases in plasma volume (less sensitive stimulus). Its normal plasma level is very low (about 1 pg/ml, i.e. 10–12 M), close to the detection limit of present immunoassays, and distinct antidiuretic effects are observed after infusion of small undetectable amounts of VP. (2) This antidiuretic action results from three main effects of VP on principal cells of the collecting duct (CD) mediated by occupancy of peritubular V2 receptors. (i) Increase in water permeability along the entire CD (via AQP2). (ii) Increase in urea permeability in only the terminal inner medullary CD (via UT-A1). (iii) Stimulation of sodium reabsorption, mainly in the cortical and outer medullary CD (via ENaC). VP also acts on medullary vasculature (V1a receptors) to reduce blood flow to inner medulla without affecting blood flow to outer medulla. Besides these actions, all concurring to increase urine osmolality in different and additive ways, other VP effects, probably exerted through V1a receptors located on luminal membrane, tend to limit the antidiuretic effects of the hormone. They induce the formation of prostaglandins which reduce V2-dependent cAMP accumulation in these cells and thus partially inhibit all three V2 effects. (3) Because urine is first diluted along the nephron before being concentrated in the medulla, VP is required, not only for urine concentration, but first for re-equilibration of tubular fluid osmolality with plasma osmolality, a step taking place in the renal cortex, and achieved through the reabsorption of large quantities of water (more than what is subsequently reabsorbed in the medulla to concentrate urine). Accordingly, VP effects on urine flow-rate are not linear. Small changes in plasma VP in the low range of urine osmolality will induce wide changes in urinary flow-rate, whereas in the upper range of urine osmolality larger changes in plasma VP induce much more limited further reduction in urine flow-rate. (4) Most likely, the different effects of VP require different levels of VP concentration to occur and are thus recruited successively with progressive rise in VP secretion.
KEYWORDS VP, Vasopressin; ADH, Antidiuretic hormone (=vasopressin); dDAVP, deamino-8D-arginine vasopressin; DI, Diabetes insipidus; V1aR, V1bR, V2R, VP receptors V1a, V1B and V2; PVP, Plasma vasopressin concentration; Posm, Plasma osmolality; Uosm, Urine osmolality; CH2O, Solute-free water clearance; TcH2O, Solute-free water reabsorption; GFR, Glomerular filtration rate; TAL, Thick ascending limb of Henle's loop; DCT, Distal convoluted tubule; CNT, Connecting tubule; CD, Collecting duct; CCD, Cortical collecting duct; IMCD, Inner medullary collecting duct; OM, Outer medulla; IM, Inner medulla; AQP2, Aquaporin 2; ENaC, Epithelial sodium channel; UT-A1, Urea transporter A1
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Konno, S. Hyodo, Y. Yamaguchi, H. Kaiya, M. Miyazato, K. Matsuda, and M. Uchiyama African lungfish, Protopterus annectens, possess an arginine vasotocin receptor homologous to the tetrapod V2-type receptor J. Exp. Biol., July 15, 2009; 212(14): 2183 - 2193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Torres, L. Bankir, and J. J. Grantham A Case for Water in the Treatment of Polycystic Kidney Disease Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1140 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Alonso, E. Galibert, V. Boulay, A. Guillou, A. Jean, V. Compan, and G. Guillon Sustained Elevated Levels of Circulating Vasopressin Selectively Stimulate the Proliferation of Kidney Tubular Cells via the Activation of V2 Receptors Endocrinology, January 1, 2009; 150(1): 239 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Izumi, Y. Nakayama, H. Memetimin, T. Inoue, Y. Kohda, H. Nonoguchi, and K. Tomita Regulation of V2R transcription by hypertonicity and V1aR-V2R signal interaction Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1170 - F1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Perucca, D. G. Bichet, P. Bardoux, N. Bouby, and L. Bankir Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1721 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bishara, H. Shiekh, T. Karram, I. Rubinstein, Z. S. Azzam, N. Abu-Saleh, S. Nitecki, J. Winaver, A. Hoffman, and Z. A. Abassi Effects of Novel Vasopressin Receptor Antagonists on Renal Function and Cardiac Hypertrophy in Rats with Experimental Congestive Heart Failure J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 414 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Finley IV, M. A. Konstam, and J. E. Udelson Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia Circulation, July 22, 2008; 118(4): 410 - 421. [Full Text] [PDF]
|
|
|
|
|
|
V. E. Torres Role of Vasopressin Antagonists Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1212 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Windt, A. Tahara, A. C. Kluppel, D. de Zeeuw, R. H Henning, and R. P. van Dokkum Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 217 - 224. [Abstract] [PDF]
|
|